Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014

By sjmartinez • September 6, 2024

Bahlis NJ, Samaras C, Reece D, Sebag M, Matous J, Berdeja JG, Shustik J, Schiller GJ, Ganguly S, Song K, Seet CS, Acosta-Rivera M, Bar M, Quick D, Fonseca G, Liu H, Gentili C, Singh P, Siegel D. Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014. Clin Lymphoma Myeloma Leuk. 2024 Aug 8:S2152-2650(24)00285-4. doi: 10.1016/j.clml.2024.07.014. Epub ahead of print. PMID: 39237427.

Tags: DPd, efficacy, Hematology/Oncology, Immunomodulatory agent, Lenalidomide-exposed, Publications, Toxicity management

Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy

Isaacs DJ, Kathuria-Prakash N, Hilder R, Lechner MG, Drakaki A. Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint[...]

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer

Bang YH, Lee CK, Bang K, Kim HD, Kim KP, Jeong JH, Park I, Ryoo BY, Lee DK, Choi HJ, Chung T, Jeon SH, Shin[...]

Feasibility of a blood pressure telemedicine program in the virtual age

Sreekrishnan A, Lansberg M, Singer AE, Tennant RS, Howard M, Buncom J, Castillo M, Rajasekhar V, Kraler L. Feasibility of a blood pressure telemedicine program[...]